期刊文献+

隐匿性乳腺癌的临床诊治及分析 被引量:6

下载PDF
导出
摘要 目的探讨隐匿性乳腺癌的临床诊断、治疗以及预后,分析影响因素。方法对隐匿性乳腺癌46例的临床资料回顾性分析,对其诊断治疗方法以及治疗效果进行总结分析。结果隐匿性乳腺癌46例,其中23例隐匿性乳腺癌患者以腋窝肿块为首发症状,采用同侧乳腺改良根治术;19例采取同侧腋窝淋巴结清扫术,4例粗针穿刺腋窝淋巴结活检确诊隐匿性乳腺癌,未进行手术治疗并所有患者辅以化、放疗综合治疗。经跟踪随访6个月至9年,术后随访平均7.3年,腋窝淋巴结清扫术组6月、1年、5年生存率分别为94.74%、78.95%、63.16%;乳腺改良根治术组患者6月、1年、5年生存率分别为95.65%、82.61%、69.57%,两组各随访时间生存率差异无统计学意义(P>0.05),但腋窝淋巴结清扫术组患者5年复发率(31.58%)高于改良根治术组(P<0.05)。结论腋窝淋巴结活检为隐匿性乳腺癌的重要检查,应及时的给予诊治,目前治疗方式为改良根治术并辅以化、放疗综合治疗,临床效果满意。
出处 《临床和实验医学杂志》 2013年第3期214-215,共2页 Journal of Clinical and Experimental Medicine
  • 相关文献

参考文献7

二级参考文献44

  • 1孙祝生,郭建琳.隐性乳腺癌20例诊治分析[J].新疆医科大学学报,2005,28(11):1061-1062. 被引量:1
  • 2骆成玉.乳腔镜在乳腺癌治疗中的应用与评价[J].中国实用外科杂志,2006,26(4):309-311. 被引量:27
  • 3刘鹏,苏轶男,刘艳,张瑾.隐性乳腺癌的诊治(附68例报告)[J].中国肿瘤临床,2007,34(7):391-393. 被引量:14
  • 4范宇 傅西林.乳腺癌常用免疫组化指标及临床应用[A].李树玲主编.乳腺肿瘤学[C].北京:科学技术文献出版社,2000.111-113.
  • 5[1]Maunsell E,Brisson J,Deschenes L.Arm problems and psychological distress after surgery for breast cancer[J].Can J Surg,1993,36:315-320.
  • 6[2]Warmuth M A,Bowen G,Prosnitz L R,et al.Complications of axillary lymph node dissection for carcinoma of the breast:a report based on a patient survey[J].Cancer,1998,83:1362-1368.
  • 7[4]Suzanne F,Finketin F,Lemery D,et al.New non traumatic technique for axillary lymphadenectomy using fat and lymph nodes suction aspiration.A study of 30 cases[J].Breast Cancer Res Treat,1993,27:288.
  • 8[5]Gomatos I P,Filippakis G,Albanopoulos K,et al.Complete endoscopic axillary lymph node dissection without liposuction for breast cancer:initial experience and mid-term outcome[J].Surg Laparosc Endosc Percutan Tech,2006,16:232-236.
  • 9[6]Kuehn T,Santjohanser C,Grab D,et al.Endoscopic axillary surgery in breast cancer[J].Br J Surg,2001,88:698-703.
  • 10[7]Brun J L,Belleannee G,Rousseau E,et al.Does axillary liposuction modify histologic study of excised lymph nodes[J].J Gynecol Obstet Biol Reprod,1997,26:503-506.

共引文献55

同被引文献42

  • 1牛昀,范宇,傅西林.隐性乳腺癌的全乳腺次连续大切片检查[J].中华肿瘤杂志,1995,17(4):298-300. 被引量:34
  • 2蔡海峰,赵刚,潘惠承.新辅助化疗在隐匿性乳腺癌中的应用[J].中国综合临床,2006,22(6):538-539. 被引量:4
  • 3Wolff AC,Hammond ME,Schwartz JN.American society of clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25 (1):118-145.
  • 4Hicks DG,Kulkarni S.HER2 + breast cancer:review of biologic relevance and optimal use of diagnostic tools[J].Am J Clin Pathol,2008,129 (2):263-273.
  • 5Hicks DG,Kulkarni S.Trastuzumab as adjuvant therapy for early breast cancer:the importance of accurate human epidermal growth factor receptor 2 testing[J].Arch Pathol Lab Med,2008,132 (6):1008-1015.
  • 6Chan SW,Cheung PS,Chan S,et al.Benefit of ultrasonography in the detection of clinically and mammographically occult breast cancer[J].World J Surg,2008,32(12):2593-2598.
  • 7Hulka CA,Smith BL,Sgroi DC.Benign and malignant breast lesions:differentiation with echo-planar MR imaging[J].Radiology,1995,197(1):33-38.
  • 8Halsted WS. The results of radical operation for the cure of car- cinoma of the breast[J]. AnnSurg,1907,46:1-19.
  • 9Llawes D, Neville .AM, Cote RI. Detection of occult metastasis in pa- tients with breast cancer[J]. Semin Surg Oncol, 2010,20 (4) : 312.
  • 10Walter B. Not every form of breast cancer can be demarcated with MRI[J]. Radiology, 2010,50 (10) : 843-844.

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部